Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer

被引:41
作者
Sabet, Amir [1 ]
Meyer, Carsten [2 ]
Aouf, Anas [1 ]
Sabet, Amin [1 ]
Ghamari, Shahab [1 ]
Pieper, Claus C. [2 ]
Mayer, Karin [3 ]
Biersack, Hans-Juergen [1 ]
Ezziddin, Samer [1 ,4 ]
机构
[1] Univ Hosp, Dept Nucl Med, Bonn, Germany
[2] Univ Hosp, Dept Radiol, Bonn, Germany
[3] Univ Hosp, Dept Med & Oncol, Bonn, Germany
[4] Univ Saarland, Dept Nucl Med, Homburg, Germany
关键词
CRC; SIRT; FDG PET; Radioembolization; Response; POSITRON-EMISSION-TOMOGRAPHY; CAPECITABINE PLUS OXALIPLATIN; NON-HODGKINS-LYMPHOMA; PHASE-III TRIAL; HEPATIC METASTASES; RESPONSE EVALUATION; RESIN MICROSPHERES; 1ST-LINE TREATMENT; ESOPHAGEAL CANCER; PROGRESSION-FREE;
D O I
10.1007/s00259-014-2935-z
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim of this study was to evaluate the predictive value of early metabolic response 4 weeks post-treatment using F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in patients with unresectable hepatic metastases of colorectal cancer (CRC) undergoing radioembolization (RE) with Y-90-labelled microspheres. A total of 51 consecutive patients with liver-dominant metastases of CRC were treated with RE and underwent F-18-FDG PET/CT at baseline and 4 weeks after RE. In each patient, three hepatic metastases with the highest maximum standardized uptake value (SUVmax) were selected as target lesions. Metabolic response was defined as > 50 % reduction of tumour to liver ratios. Survival analyses using Kaplan-Meier and multivariate analyses were performed to identify prognostic factors for overall survival (OS). Investigated baseline characteristics included age (> 60 years), performance status (Eastern Cooperative Oncology Group > 1), bilirubin (> 1.0 mg/dl), hepatic tumour burden (> 25 %) and presence of extrahepatic disease. The median OS after RE was 7 months [95 % confidence interval (CI) 5-8]; early metabolic responders (n = 33) survived longer than non-responders (p < 0.001) with a median OS of 10 months (95 % CI 3-16) versus 4 months (95 % CI 2-6). Hepatic tumour burden also had significant impact on treatment outcome (p < 0.001) with a median OS of 5 months (95 % CI, 3-7) for patients with > 25 % metastatic liver replacement vs 14 months (95 % CI 6-22) for the less advanced patients. Both factors (early metabolic response and low hepatic tumour burden) remained as independent predictors of improved survival on multivariate analysis. These are the first findings to show that molecular response assessment in CRC using F-18-FDG PET/CT appears feasible as early as 4 weeks post-RE, allowing risk stratification and potentially facilitating early response-adapted treatment strategies.
引用
收藏
页码:370 / 376
页数:7
相关论文
共 45 条
  • [1] Radioembolization of Liver Tumors With Yttrium-90 Microspheres
    Ahmadzadehfar, Hojjat
    Biersack, Hans-Juergen
    Ezziddin, Samer
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2010, 40 (02) : 105 - 121
  • [2] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Andre, T
    Boni, C
    Mounedji-Boudiaf, L
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Zaninelli, M
    Clingan, P
    Bridgewater, J
    Tabah-Fisch, I
    de Gramont, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2343 - 2351
  • [3] Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study
    Benson, Al B., III
    Geschwind, Jean-Francois
    Mulcahy, Mary F.
    Rilling, William
    Siskin, Gary
    Wiseman, Greg
    Cunningham, James
    Houghton, Bonny
    Ross, Mason
    Memon, Khairuddin
    Andrews, James
    Fleming, Chad J.
    Herman, Joseph
    Nimeiri, Halla
    Lewandowski, Robert J.
    Salem, Riad
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (15) : 3122 - 3130
  • [4] Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
    Cassidy, Jim
    Clarke, Stephen
    Diaz-Rubio, Eduardo
    Scheithauer, Werner
    Figer, Arie
    Wong, Ralph
    Koski, Sheryl
    Lichinitser, Mikhail
    Yang, Tsai-Shen
    Rivera, Fernando
    Couture, Felix
    Sirzen, Florin
    Saltz, Leonard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2006 - 2012
  • [5] Can "early" and "late" 18F-FDG PET-CT be used as prognostic factors for the clinical outcome of patients with locally advanced head and neck cancer treated with radio-chemotherapy?
    Castaldi, Paola
    Rufini, Vittoria
    Bussu, Francesco
    Micciche, Francesco
    Dinapoli, Nicola
    Autorino, Rosa
    Lago, Mariaelena
    De Corso, Eugenio
    Almadori, Giovanni
    Galli, Jacopo
    Paludetti, Gaetano
    Giordano, Alessandro
    Valentini, Vincenzo
    [J]. RADIOTHERAPY AND ONCOLOGY, 2012, 103 (01) : 63 - 68
  • [6] Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma:: prevalence and scan interpretation
    Castellucci, P
    Nanni, C
    Farsad, M
    Alinari, L
    Zinzani, P
    Stefoni, V
    Battista, G
    Valentini, D
    Pettinato, C
    Marengo, M
    Boschi, S
    Canini, R
    Baccarani, M
    Monetti, N
    Franchi, R
    Rampin, L
    Fanti, S
    Rubello, D
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2005, 26 (08) : 689 - 694
  • [7] Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases
    Cosimelli, M.
    Golfieri, R.
    Cagol, P. P.
    Carpanese, L.
    Sciuto, R.
    Maini, C. L.
    Mancini, R.
    Sperduti, I.
    Pizzi, G.
    Diodoro, M. G.
    Perrone, M.
    Giampalma, E.
    Angelelli, B.
    Fiore, F.
    Lastoria, S.
    Bacchetti, S.
    Gasperini, D.
    Geatti, O.
    Izzo, F.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 103 (03) : 324 - 331
  • [8] Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer
    de Geus-Oei, L. F.
    van Laarhoven, H. W. M.
    Visser, E. P.
    Hermsen, R.
    van Hoorn, B. A.
    Kamm, Y. J. L.
    Krabbe, P. F. M.
    Corstens, F. H. M.
    Punt, C. J. A.
    Oyen, W. J. G.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (02) : 348 - 352
  • [9] de Geus-Oei Lioe-Fee, 2006, Cancer Imaging, V6, pS71, DOI 10.1102/1470-7330.2006.9014
  • [10] Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer
    Edwards, Brenda K.
    Noone, Anne-Michelle
    Mariotto, Angela B.
    Simard, Edgar P.
    Boscoe, Francis P.
    Henley, S. Jane
    Jemal, Ahmedin
    Cho, Hyunsoon
    Anderson, Robert N.
    Kohler, Betsy A.
    Eheman, Christie R.
    Ward, Elizabeth M.
    [J]. CANCER, 2014, 120 (09) : 1290 - 1314